On the basis of the different trend of IHC expression obtained with C-term and N-term LAL antibodies in this subset of patients, the analysis was extended to a cohort of 87 NAFLD patients, who were studied by IHC with the antibody recognizing the N-term non-ubiquitinated/functional LAL. The gene discussed is LIPA; the disease is metabolic dysfunction-associated steatotic liver disease.